MedPath

Effects of Intranasal Oxytocin on Emotion Regulation in Adolescents

Phase 1
Completed
Conditions
Parent-Child Relations
Emotion
Interventions
Drug: Placebo
Registration Number
NCT02301715
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Brief Summary

The purpose of this study is to determine the effect of intranasal administration of OT on behavior and discourse of insecure adolescents during a disagreement (stressful situation) with parents.

Detailed Description

Emotional dysregulation and impaired attachment in adolescence are seen by clinical researchers as potential contributors to development of psychopathology. Recent evidence suggests that administration of intranasal OT may facilitate social interaction by attenuating the stress response to interpersonal conflict. However, to date there have been no studies investigating the effects of intranasal OT on parent-adolescent interaction and on neurophysiological emotional strategies in adolescence. To understand these mechanisms, this study examines the effects of OT on interpersonal emotional regulation in adolescent-parent stressful interaction, and on individual visual and physiological strategies in the visualizing attachment-related emotions pictures.

The main objective will be to evaluate the effect of intranasal administration of OT on behavior and discourse of insecure adolescents during a disagreement (stressful situation) with one of his parents.

Secondary is determine the effect of OT on visual exploration strategies and on the physiological responses (heart rate, galvanic skin response) on images elicited attachment-related emotions in insecure adolescents.

In this randomized, double-blind, placebo-controlled, parallel designs, 60 healthy male adolescents classified with an insecure attachment will receive 24 IU of intranasal OT or placebo, 45 min before the experimental tasks. Adolescent will be invited with his/her parent to an experimental conflict discussion. The conflict session will be videotaped and coded for verbal and nonverbal interaction behavior (e.g., eye contact, nonverbal positive/negative behavior, and self-disclosure) with GPACS. Eye tracking and physiological responses will be recorded simultaneously and continuously during pictures viewing.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
29
Inclusion Criteria
  • Have a clinical diagnosis of insecure attachment according to the Attachment Scale Interview
  • Male adolescents (and parents) enrolled in high school or college
  • Not hospitalized
  • Without current or past history of neurological or psychiatric illness, including substance abuse or dependence
  • Aged from 13 to 20 years
  • Speaking French
  • Have signed informed consent
  • Affiliation to a French social security
Exclusion Criteria
  • Females
  • Intellectual deficit
  • Severe neurological symptoms
  • Known allergies to oxytocin or to preservatives in the nasal spray
  • Not speaking French
  • Visual disturbances
  • Chronic disease (liver failure, kidney failure, cardiovascular disease)
  • Antihypertensive therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebointranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment
OxytocinOxytocin24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment
Primary Outcome Measures
NameTimeMethod
Conflict discussion3 years

Adolescent will be invited with his/her parent to an experimental conflict discussion. The conflict session will be videotaped and coded for verbal and nonverbal interaction behavior (e.g., eye contact, nonverbal positive/negative behavior, and self-disclosure) with GPACS.Behavioral data will be collected during each of the study visits. Drug effect will be determined by comparing data obtained during placebo and oxytocin visits.

Secondary Outcome Measures
NameTimeMethod
Visual patterns3 years

Adolescent's eye tracking (i.e., time (ms) and frequency of fixations in an AOI) and physiological (Amplitude of SCL (microsiemens), Amplitude of SCRs (microsiemens), Time of latency (s)) responses will be recorded simultaneously and continuously during pictures viewing.

Trial Locations

Locations (1)

University Regional Hospital

🇫🇷

Besançon, Franche-Comté, France

© Copyright 2025. All Rights Reserved by MedPath